Revolutionizing RNA Therapy: Orna Therapeutics' Innovative panCAR™ Approach Unveiled at ASH 2024#United_States#San_Diego#Orna_Therapeutics#panCAR™#RNA_Delivery
Revolutionizing RNA Therapy: Orna Therapeutics' Innovative panCAR™ Approach Unveiled at ASH 2024
Orna Therapeutics showcased groundbreaking data at ASH 2024, highlighting its panCAR™ platform's effectiveness in delivering RNA for B cell-mediated diseases, promising new treatment pathways.
third-news.com
December 9, 2024 at 2:16 PM
Revolutionizing RNA Therapy: Orna Therapeutics' Innovative panCAR™ Approach Unveiled at ASH 2024#United_States#San_Diego#Orna_Therapeutics#panCAR™#RNA_Delivery
Ractigen Therapeutics Secures Over $31 Million to Propel saRNA Development and Delivery Innovations#China#RNA_Delivery#Ractigen_Therapeutics#Nantong#saRNA
Ractigen Therapeutics Secures Over $31 Million to Propel saRNA Development and Delivery Innovations
Ractigen Therapeutics has raised over $31 million to enhance its saRNA pipeline and proprietary delivery technologies, advancing key clinical programs.
third-news.com
July 29, 2026 at 2:09 PM
Ractigen Therapeutics Secures Over $31 Million to Propel saRNA Development and Delivery Innovations#China#RNA_Delivery#Ractigen_Therapeutics#Nantong#saRNA
Mana.bio Welcomes Laura Sepp-Lorenzino to Scientific Advisory Board, Strengthening RNA Delivery Innovations#Israel#Tel_Aviv#RNA_Delivery#Mana.bio#Laura_Sepp-Lorenzino
Mana.bio Welcomes Laura Sepp-Lorenzino to Scientific Advisory Board, Strengthening RNA Delivery Innovations
Mana.bio has appointed Laura Sepp-Lorenzino, a leader in genetic medicine, to its Scientific Advisory Board, enhancing its RNA delivery capabilities.
third-news.com
July 27, 2026 at 1:19 PM
Mana.bio Welcomes Laura Sepp-Lorenzino to Scientific Advisory Board, Strengthening RNA Delivery Innovations#Israel#Tel_Aviv#RNA_Delivery#Mana.bio#Laura_Sepp-Lorenzino
Mana.bio Expands Leadership Team and Prepares for ASGCT 2026 Presentation on AI-Driven RNA Delivery Innovations#Israel#Tel_Aviv#RNA_Delivery#Mana.bio#ASGCT_2026
Mana.bio Expands Leadership Team and Prepares for ASGCT 2026 Presentation on AI-Driven RNA Delivery Innovations
Mana.bio is set to unveil new AI-driven RNA delivery advancements at ASGCT 2026 while expanding its leadership team with industry veterans.
third-news.com
May 5, 2026 at 12:42 PM
Mana.bio Expands Leadership Team and Prepares for ASGCT 2026 Presentation on AI-Driven RNA Delivery Innovations#Israel#Tel_Aviv#RNA_Delivery#Mana.bio#ASGCT_2026
Mana.bio Launches Mina™: An AI Agent Revolutionizing RNA Delivery Technology#USA#Boston#RNA_Delivery#Mana.bio#Mina™
Mana.bio Launches Mina™: An AI Agent Revolutionizing RNA Delivery Technology
Discover how Mana.bio introduces Mina™, the pioneering AI agent designed for lipid nanoparticles, aimed at transforming RNA delivery in biotechnology.
third-news.com
September 17, 2025 at 1:42 PM
Mana.bio Launches Mina™: An AI Agent Revolutionizing RNA Delivery Technology#USA#Boston#RNA_Delivery#Mana.bio#Mina™
MOTE Therapeutics Appoints MaryJane Rafii to Accelerate RNA Delivery Solution Expansion#United_States#Boston#RNA_Delivery#MOTE_Therapeutics#MaryJane_Rafii
MOTE Therapeutics Appoints MaryJane Rafii to Accelerate RNA Delivery Solution Expansion
MOTE Therapeutics has appointed MaryJane Rafii as Chief Investment and Business Officer to boost the global growth of its RNA delivery platform and enhance fundraising efforts.
third-news.com
July 3, 2025 at 10:15 AM
MOTE Therapeutics Appoints MaryJane Rafii to Accelerate RNA Delivery Solution Expansion#United_States#Boston#RNA_Delivery#MOTE_Therapeutics#MaryJane_Rafii